Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity

The importance for immunoregulation for long-term cancer control

(2017) Alberto Fusi et al.   Future Oncology

Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses

(2017) Abhishek D. Garg et al.   IMMUNOLOGICAL REVIEWS

Immunomodulatory effects of heat-killed Mycobacterium obuense on human blood dendritic cells

(2017) Samer Bazzi et al.   Innate Immunity

Erratum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

(2016) Angus G Dalgleish et al.   BRITISH JOURNAL OF CANCER

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

A heat-killed preparation of mycobacterium obuense can reduce metastatic burden in vivo

(2014) Daniel Fowler et al.   Journal for ImmunoTherapy of Cancer

Organization of the mouse and human DC network

(2013) Andreas Schlitzer et al.   CURRENT OPINION IN IMMUNOLOGY

An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma

(2011) J. Stebbing et al.   ANNALS OF ONCOLOGY

Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy

(2011) Daniel W. Fowler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

(2008) D.S. Green et al.   BRITISH JOURNAL OF DERMATOLOGY